4 results
P
healthy participants (n = 929)
I/C
administration of a public speech task, sex differences
O
HRV
P
CYP2D6 genetic polymorphisms, metoprolol
I/C
CYP2D6 polymorphism, metoprolol treatment, CYP2D6 poor metabolizers (PM), non-PM individuals
O
heart rate (HR) reduction, diastolic (DBP) and systolic (SBP) blood pressure reduction, average daily doses, all-type adverse events, bradycardia
P
patients with mood disorders or pain control
I/C
duloxetine administration, control groups
O
cardiovascular adverse events (hypertension, myocardial infarction, transient ischemic attack, tachycardia atrial fibrillation, and cerebrovascular accident)
P
1831 participants
I/C
IOCM, LOCM
O
vascular attenuation, image quality, heart rate changes, common patient discomfort symptoms
